.

Pharmaceutical Business Intelligence

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,882,721

« Back to Dashboard

Which drugs does patent 8,882,721 protect, and when does it expire?

Patent 8,882,721 protects ADLYXIN and is included in one NDA.

This patent has twenty-three patent family members in nineteen countries.

Summary for Patent: 8,882,721

Title:Drive assembly suitable for use in a drug delivery device and drug delivery device
Abstract: A drive assembly for use in a drug delivery device is proposed, the drive assembly comprising: a housing having a proximal end and a distal end; an axis extending between the proximal end and the distal end; at least one drive member; a piston rod adapted to be driven along the axis by the drive member; an indicator adapted to provide positional information about a position of the piston rod relative to the proximal end, wherein the indicator and the piston rod are configured to convert a movement of the piston rod with respect to the housing into a rotational movement of the indicator. Additionally, a drug delivery device comprising the drive assembly is provided for.
Inventor(s): Jones; Matthew Meredith (Warwick, GB), Plumptre; David Aubrey (Droitwich, GB)
Assignee: Sanofi-Aventis Deutschland GmbH (Frankfurt am Main, DE)
Application Number:12/991,471
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-001Jul 27, 2016RXYesYes8,882,721► SubscribeY
Sanofi-aventis Us
ADLYXIN
lixisenatide
SOLUTION;SUBCUTANEOUS208471-002Jul 27, 2016RXYesYes8,882,721► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,882,721

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08009260May 20, 2008
08011676Jun 27, 2008
PCT Information
PCT FiledMay 09, 2009PCT Application Number:PCT/EP2009/003310
PCT Publication Date:November 26, 2009PCT Publication Number: WO2009/141067

International Patent Family for Patent: 8,882,721

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand589316► Subscribe
Malaysia150985► Subscribe
Mexico2010012277► Subscribe
South Korea101577944► Subscribe
South Korea20110022607► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc